Clinical trial of TS-1 + CDDP + Trastuzumab-3 weekly cycle in HER2-positive advanced gastric cancer - Clinical trial of TS-1 + CDDP + Trastuzumab-3 weekly cycle

Dokkyo Medical University0 个研究点目标入组 8 人开始时间: 2013年2月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients who are contraindicated to S-1, CDDP, and Trastuzumab. 2. Women in pregnancy, at risk of pregnancy, hoping to become pregnant. Men who want their partners to become pregnant. 3. Patients with active infection. 4. Patients have Active hepatitis type B. 5.Serious illness or medical conditions as defined below; a. Patient with a previous history of congestive heart failure b. Hi-risk uncontrolled arrhythmias c. Unstable angina requiring medication d. Patient with a previous history of myocardial infarction e. Severe heart valve disease f. Patient with a previous history of transmural infarct g. Uncontrolled hypertension 6. Serious complication as followings ; a. Interstitial pneumonia b. Pulmonary fibrosis c. Heart failure d. Renal failure e. Hepatic failure f. Uncontrolled diabetes mellitus 7. Patients with fresh bleeding from gastric cancer and/or the digestive tract 8. Patients with diarrhea (4 or more times per day or watery diarrhea). 9.Second primary malignancy (except adequately treated basal cell carcinoma treated more than 5 years ago without recurrence) 10. Patients who are received systemic continuous administration of flucytosine, phenytoin, or warfarin. 11. Any patients judged by the investigator to be unfit to participate in the study.

发起方